Expensive Gene Therapy Approved in Europe

Nov 5, 2012, 14:00 PM by Michael Croft

Reuters | Europe has approved an expensive gene therapy. Glybera treats the genetic disorder lipoprotein lipase deficiency (LPLD) and will cost around 1.2 million euros ($1.6 million) per patient.

November 5, 2012 | Europe has approved an expensive gene therapy. Glybera treats the genetic disorder lipoprotein lipase deficiency (LPLD) and will cost around 1.2 million euros ($1.6 million) per patient. Reuters